Table 2.
Summary of the main studies evaluating patient characteristics at presentation and renal outcomes of different FSGS variants.
| Study (patients) |
Age (years) | Ethnicity | Baseline nephrotic syndrome (%) | Baseline renal function | Remission (%) | Renal outcomes |
|---|---|---|---|---|---|---|
| Chun et al. 2004 [14] (n = 87) | NOS/perihilar: 40 ± 17 Cell + coll: 38 ± 16 Tip: 53 ± 17 |
% Black race
NOS/perihilar: 47 Cell + coll: 72 Tip: 44 |
NOS/perihilar: 75 Cell + Coll: 84 Tip: 100 |
Cr (mg/dl): NOS: 1.4 ± 0.5 Cell + coll: 1.9 ± 1.4 Tip: 1.6 ± 0.8 |
CR/PR/CR + PR
NOS/perihilar: 16.7/13.9/30.6 Cell + coll: 15/30/45 Tip: 45.4/18.2/63.6 |
% ESRD
NOS/perihilar: 25 Cell + coll: 43 Tip: 27 |
|
| ||||||
| Stokes et al. 2006 [15] (n = 225) | All: 37.7 ± 1.3 NOS: 32.5 ± 2.0 Cell: 48.8 ± 4.9 Coll 31.2 ± 2.3 Tip: 47.5 ± 2.3 |
% Black race
All: 31.5 NOS: 28.9 Cell: 31.8 Coll: 53.6 Tip: 13.8 |
All: 75.5 NOS: 52.9 Coll: 85.5 Cell: 86.4 Tip: 94.8 |
Cr (mg/dl): All: 2.3 ± 0.2 NOS: 1.9 ± 0.2 Cell: 1.9 ± 0.3 Coll: 3.9 ± 0.6 Tip: 1.5 ± 0.1 |
CR/PR/CR + PR
All: 27.3/11.2/38.5 NOS: 24.1/14.5/38.6 Cell: 38.9/5.5/44.4 Coll: 7.5/5.7/13.2 Tip: 60.6/15.2/75.8 |
% ESRD
All: 30.7 NOS: 34.5 Cell: 27.8 Coll: 65.3 Tip: 5.7 |
|
| ||||||
| Thomas et al. 2006 [16] (n = 197) | All: 49 ± 15 NOS: 50 ± 15 Cell: 45 ± 13 Coll: 38 ± 12 Tip: 54 ± 13 Perihilar: 50 ± 16 |
% Black race
All: 40 NOS: 43 Cell: 33 Coll: 91 Tip: 15 Perihilar: 29 |
All: 70 NOS: 67 Cell: 75 Coll: 83 Tip: 88 Perihilar: 55 |
Cr (mg/dl): All: 2.1 ± 2.0 NOS: 2.1 ± 1.8 Cell: 2.5 ± 1.7 Coll: 3.1 ± 3.8 Tip: 1.5 ± 0.9 Perihilar: 2.0 ± 1.4 |
CR/(CR or PR)
All: 19/24 NOS: 13/16 Cell: 33/33 Coll: 14/18 Tip: 50/53 Perihilar: 10/19 |
% Renal survival
+
3-year
All: 67 NOS: 65 Cell: NA Coll: 33 Tip: 76 Perihilar: 75 |
|
| ||||||
| Paik et al. 2007 [17] (n = 92) | All: 6.7 ± 3.5 | N/A | All: 92.4 |
Cr (mg/dl): All: 0.77 ± 0.50 |
CR/PR
All: 39.1/15.2/54.3 |
% ESRD All: 21.7% % Renal survival ‡ 5-year: 84 10-year: 64 15-year: 53 |
|
| ||||||
| Silverstein and Craver 2007 [18] (n = 41) |
All: 10.9 ± 0.9 | % Black race
All: 80.5% |
All: 63.4 NOS: 55.6 Cell: 81.8 Coll: 54.5 |
eGFR (ml/min/1.73 m
2
)
All: 105.4 ± 4.6 NOS: 116.5 ± 4.9 Cell: 107.6 ± 7.2 Coll: 88.2 ± 10.7 |
CR + PR
All: 71 NOS: 72.2 Cell: 75 Coll: 45.4 |
% CKD stage 5
NOS: 0 Cell: 0 Coll: 18.2 |
|
| ||||||
| Deegens et al. 2008 [19] (n = 93) | All: 49 ± 16 NOS: 51 ± 17 Collapsing: 63 ± 18 Tip: 44 ± 16 Perihilar: 50 ± 12 |
% Dutch descent: All: 96 NOS: 93 Collapsing: 100 Tip: 97 Perihilar: 96 |
% NS:
All: 63 NOS: 57 Collapsing: 80 Tip: 97 Perihilar: 25 |
Cr (mg/dl): All: 1.7 ± 1.1 NOS: 1.99 ± 1.3 Collapsing: 2.2 ± 1.6 Tip: 1.3 ± 0.9 Perihilar: 1.6 ± 0.99 |
CR + PR
All: 44 NOS: 38 Collapsing: 50 Tip: 57 Perihilar: 25 |
% Renal survival
~
5-year
All: 66 NOS: 63 Collapsing: 30 Tip: 78 Perihilar: 55 |
|
| ||||||
| D'Agati et al. 2013 [20] (n = 138) | NOS: 13 Coll: 16.5 Tip: 15 |
% Black race: NOS: 39 Coll: 63 Tip: 14 |
% severe/intermed. nephrosis
*: NOS: 69 Tip: 93 Coll: 94 |
Cr (mg/dl): NOS: 0.86 ± 0.61 Tip: 0.84 ± 0.43 Coll: 1.33 ± 0.50 |
N/A | % ESRD at 3 yrs
NOS: 20 Coll: 47 Tip: 7 |
*Intermediate nephrosis = U p/c > 2 and ≤6 g/g or serum albumin ≥1.5 and <2.5 g/dl; severe nephrosis = Up/c > 6 g/g or serum albumin <1.5 g/dl.
+Renal failure = sustained doubling of the serum creatinine or initiation of chronic dialysis or kidney transplantation.
‡Renal survival = measured from date of presentation to diagnosis of CRF.
~Renal failure = sustained increase of the serum Cr concentration of >50% from baseline or development of ESRD.